PL358271A1 - 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny - Google Patents

5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny

Info

Publication number
PL358271A1
PL358271A1 PL01358271A PL35827101A PL358271A1 PL 358271 A1 PL358271 A1 PL 358271A1 PL 01358271 A PL01358271 A PL 01358271A PL 35827101 A PL35827101 A PL 35827101A PL 358271 A1 PL358271 A1 PL 358271A1
Authority
PL
Poland
Prior art keywords
alkylpyrido
pyrimidines
tyrosine kinase
kinase inhibitors
inhibitors
Prior art date
Application number
PL01358271A
Other languages
English (en)
Polish (pl)
Inventor
Richard John Booth
Ellen Mayra Dobrusin
Peter Laurence Toogood
Scott Norman Vanderwell
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of PL358271A1 publication Critical patent/PL358271A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL01358271A 2000-03-06 2001-01-29 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny PL358271A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
PCT/US2001/002657 WO2001070741A1 (fr) 2000-03-06 2001-01-29 Inhibiteurs de tyrosine kinase a base de 5-alkylpyrido[2,3-d]pyrimidines

Publications (1)

Publication Number Publication Date
PL358271A1 true PL358271A1 (pl) 2004-08-09

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01358271A PL358271A1 (pl) 2000-03-06 2001-01-29 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny

Country Status (37)

Country Link
EP (1) EP1268476A1 (fr)
JP (1) JP2003528101A (fr)
KR (1) KR20020075805A (fr)
CN (1) CN1422268A (fr)
AP (1) AP2002002643A0 (fr)
AR (1) AR034119A1 (fr)
AU (1) AU2001233028A1 (fr)
BG (1) BG107161A (fr)
BR (1) BR0109056A (fr)
CA (1) CA2401368A1 (fr)
CO (1) CO5280200A1 (fr)
CR (1) CR6736A (fr)
CZ (1) CZ20022929A3 (fr)
DZ (1) DZ3308A1 (fr)
EA (1) EA200200802A1 (fr)
EE (1) EE200200506A (fr)
GT (1) GT200100037A (fr)
HN (1) HN2001000040A (fr)
HR (1) HRP20020798A2 (fr)
HU (1) HUP0300136A2 (fr)
IL (1) IL151480A0 (fr)
IS (1) IS6524A (fr)
MA (1) MA26881A1 (fr)
MX (1) MXPA02008535A (fr)
NO (1) NO20024235L (fr)
NZ (1) NZ520962A (fr)
OA (1) OA12227A (fr)
PA (1) PA8513201A1 (fr)
PE (1) PE20011177A1 (fr)
PL (1) PL358271A1 (fr)
PY (1) PY0104899A (fr)
SK (1) SK12472002A3 (fr)
SV (1) SV2001000338A (fr)
TN (1) TNSN01036A1 (fr)
WO (1) WO2001070741A1 (fr)
YU (1) YU66502A (fr)
ZA (1) ZA200207110B (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
CZ20032416A3 (cs) * 2001-02-12 2004-07-14 F. Hoffmann-La Roche Ag 6-Substituované pyridopyrimidiny
JP4166991B2 (ja) * 2001-02-26 2008-10-15 田辺三菱製薬株式会社 ピリドピリミジンまたはナフチリジン誘導体
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
DE60303009T2 (de) 2002-01-22 2006-07-13 Warner-Lambert Co. Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
MXPA04010267A (es) 2002-04-19 2005-02-03 Smithkline Beecham Corp Compuestos novedosos.
EP1542989B1 (fr) 2002-07-31 2007-04-18 Critical Outcome Technologies, Inc. Inhibiteurs de proteine tyrosine kinase
AU2003273675A1 (en) 2002-10-09 2004-05-04 Wayne R. Danter Protein tyrosine kinase inhibitors
JP2006516561A (ja) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
JP4053073B2 (ja) * 2003-07-11 2008-02-27 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 選択的ｃｄｋ４阻害剤のイセチオン酸塩
CA2536954C (fr) 2003-08-29 2012-11-27 Exelixis, Inc. Modulateurs c-kit et leurs procedes d'utilisation
WO2005047284A1 (fr) 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Pyrido-7-pyrimidin-7-ones substitues hydroxyalkyle
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (fr) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments
CA2575804A1 (fr) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones utilisees en tant qu'inhibiteurs des plk (polo-like-kinases)
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
WO2006076706A1 (fr) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Derives de cinnamide et d'hydrocinnamide presentant une activite inhibitrice de raf-kinase
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
US8044062B2 (en) * 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
GEP20115306B (fr) 2006-09-15 2011-10-10 Pfizer Prod Inc
BRPI0715566A2 (pt) * 2006-10-16 2013-07-02 Gpc Biotech Inc composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto
EP1914234A1 (fr) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
WO2008124323A1 (fr) * 2007-04-03 2008-10-16 Array Biopharma Inc. Composés imidazo[1,2-a]pyridine utilisés comme inhibiteurs des récepteurs à activité tyrosine kinase
CN101784551A (zh) * 2007-06-15 2010-07-21 万有制药株式会社 二环苯胺衍生物
EP2185559A1 (fr) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Forme cristalline d'un dérivé de dihydroptéridione
WO2009085185A1 (fr) 2007-12-19 2009-07-09 Amgen Inc. Composés condensés de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire
EP2225226B1 (fr) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Composés et leur utilisation dans un procédé pour le traitement du cancer
EP2100894A1 (fr) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidinones utilisés comme inhibiteurs de la kinase de type Plk1 (polo-like kinase)
MX2010010975A (es) * 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
EP2112150B1 (fr) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
EP3023426A1 (fr) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Composés inhibiteurs à base de thiosemicarbazone et procédés de traitement du cancer
AR073524A1 (es) 2008-09-30 2010-11-10 Exelixis Inc Piridopirimidinonas inhibidores de pi3k a y m tor
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CA2776770A1 (fr) * 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles de snc
CA2784749C (fr) 2009-12-18 2017-12-12 E. Premkumar Reddy Pyrido[2,3-d]pyrimidin-7(8h)-ones substitues et leurs utilisations therapeuthiques
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
DK2600719T3 (da) * 2010-08-05 2014-12-15 Univ Temple 2-substituerede 8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-carbonnitriler og anvendelser deraf
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
JP6000273B2 (ja) 2010-11-29 2016-09-28 オーエスアイ・ファーマシューティカルズ，エルエルシー 大環状キナーゼ阻害剤
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
PT2688887E (pt) 2011-03-23 2015-07-06 Amgen Inc Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
US8962831B2 (en) * 2011-05-17 2015-02-24 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP2817308B1 (fr) * 2012-02-23 2016-09-07 AbbVie Inc. Dérivés de pyridopyrimidinone et leur utilisation comme inhibiteurs de kinases
PL2958916T3 (pl) * 2013-02-21 2019-01-31 Pfizer Inc. Stałe postacie selektywnego inhibitora CDK4/6
WO2015011236A1 (fr) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Traitement du syndrome myélodysplasique
WO2016015598A1 (fr) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido [2,3-d] pyrimidin -7 (8h)-one utilisés en tant qu'inhibiteurs de cdk et utilisations de ceux-ci
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
JP6563623B1 (ja) 2016-08-15 2019-08-21 ファイザー・インク ピリドピリミジノンｃｄｋ２／４／６阻害剤
AU2018229148B2 (en) * 2017-03-03 2022-08-04 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
US11174252B2 (en) 2018-02-15 2021-11-16 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2020114519A1 (fr) * 2018-12-07 2020-06-11 杭州英创医药科技有限公司 Composé hétérocyclique à titre d'inhibiteur de la voie double cdk-hdac
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
JP7756374B2 (ja) * 2021-03-08 2025-10-20 曁南大学 ピリドピリミジン系化合物及びその使用
WO2022258023A1 (fr) * 2021-06-09 2022-12-15 郑州同源康医药有限公司 Composé utile en tant qu'inhibiteur de kinase dépendante des cyclines et son utilisation
CN117720531A (zh) * 2022-09-16 2024-03-19 华东师范大学 作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用
EP4617267A4 (fr) * 2022-11-10 2026-02-18 Prime Gene Therapeutics Co Ltd Composé thioéther ayant une propriété de médicament doux et son utilisation, composition pharmaceutique et utilisation associées
WO2024107730A1 (fr) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Méthodes et compositions pour le traitement du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
DE69839338T2 (de) * 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
EE200000706A (et) * 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid

Also Published As

Publication number Publication date
PY0104899A (es) 2003-11-03
CZ20022929A3 (cs) 2003-02-12
AU2001233028A1 (en) 2001-10-03
NO20024235D0 (no) 2002-09-05
MXPA02008535A (es) 2002-12-13
NZ520962A (en) 2003-09-26
NO20024235L (no) 2002-11-05
OA12227A (en) 2004-03-18
YU66502A (sh) 2005-09-19
EE200200506A (et) 2004-02-16
HN2001000040A (es) 2001-09-06
IS6524A (is) 2002-08-23
EA200200802A1 (ru) 2003-02-27
CA2401368A1 (fr) 2001-09-27
BR0109056A (pt) 2003-06-03
ZA200207110B (en) 2003-12-04
TNSN01036A1 (en) 2005-11-10
CN1422268A (zh) 2003-06-04
IL151480A0 (en) 2003-04-10
CR6736A (es) 2004-03-10
PE20011177A1 (es) 2001-11-23
HUP0300136A2 (en) 2003-05-28
MA26881A1 (fr) 2004-12-20
JP2003528101A (ja) 2003-09-24
BG107161A (bg) 2003-06-30
EP1268476A1 (fr) 2003-01-02
SK12472002A3 (sk) 2003-04-01
SV2001000338A (es) 2001-11-30
KR20020075805A (ko) 2002-10-05
GT200100037A (es) 2002-03-04
DZ3308A1 (fr) 2001-09-27
HRP20020798A2 (en) 2004-02-29
WO2001070741A1 (fr) 2001-09-27
CO5280200A1 (es) 2003-05-30
AP2002002643A0 (en) 2002-12-31
PA8513201A1 (es) 2003-06-30
AR034119A1 (es) 2004-02-04

Similar Documents

Publication Publication Date Title
PL358271A1 (pl) 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny
EP1161433A4 (fr) Inhibiteurs de tyrosine kinase
EE200200405A (et) Pürido[2,3-d]pürimidiin-2,7-diamiinid kui kinaasiinhibiitorid
MXPA03008690A (es) Inhibidores novedosos de tirosina cinasa.
DK1235830T3 (da) Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
NO20021820L (no) Tyrosinkinaseinhibitorer
DK1416935T3 (da) 4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater
DE60207241D1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidin-derivate
NL300242I1 (nl) Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
AU2002361577A1 (en) Tyrosine kinase inhibitors
AU2002348394A1 (en) Tyrosine kinase inhibitors
EP1259236A4 (fr) Inhibiteurs de tyrosine-kinase
AU2002348020A1 (en) Tyrosine kinase inhibitors
AU2002348393A1 (en) Tyrosine kinase inhibitors
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2002327534A1 (en) Tyrosine kinase inhibitors
AU2002253350A1 (en) 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
DE50103649D1 (de) 2-aminoalkyl-thieno[2,3-d]pyrimidine
DK1226136T3 (da) Tyrosinkinaseinhibitor
AU2002355733A1 (en) Tyrosine kinase inhibitors
AU2002304001A1 (en) Tyrosine kinase inhibitors
AU2002326758A1 (en) Tyrosine kinase inhibitors
AU2002322568A1 (en) Tyrosine kinase inhibitors
AU2002326466A1 (en) Tyrosine kinase inhibitors
AU2002326865A1 (en) Tyrosine kinase inhibitors

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)